Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.

Torres B, Ruoho AE.

Neuroscience. 2014 Feb 14;259:194-202. doi: 10.1016/j.neuroscience.2013.11.059.

2.

A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.

Bernstein AI, Stout KA, Miller GW.

J Neurosci Methods. 2012 Aug 15;209(2):357-66. doi: 10.1016/j.jneumeth.2012.06.002.

3.

Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.

Meyer AC, Horton DB, Neugebauer NM, Wooters TE, Nickell JR, Dwoskin LP, Bardo MT.

Neuropharmacology. 2011 Sep;61(4):849-56. doi: 10.1016/j.neuropharm.2011.05.033.

4.
5.

GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.

Horton DB, Nickell JR, Zheng G, Crooks PA, Dwoskin LP.

J Neurochem. 2013 Oct;127(2):177-86. doi: 10.1111/jnc.12371.

7.

Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.

Ugolev Y, Segal T, Yaffe D, Gros Y, Schuldiner S.

J Biol Chem. 2013 Nov 8;288(45):32160-71. doi: 10.1074/jbc.M113.502971.

8.

Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux.

Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A.

J Neurochem. 2006 Feb;96(4):1149-59.

9.
10.

Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.

Lohr KM, Stout KA, Dunn AR, Wang M, Salahpour A, Guillot TS, Miller GW.

ACS Chem Neurosci. 2015 May 20;6(5):790-9. doi: 10.1021/acschemneuro.5b00010.

11.

Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.

Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, Ruoho AE.

J Neural Transm (Vienna). 2009 Dec;116(12):1591-9. doi: 10.1007/s00702-009-0308-8.

PMID:
19756361
12.

Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.

Pifl C, Rajput A, Reither H, Blesa J, Cavada C, Obeso JA, Rajput AH, Hornykiewicz O.

J Neurosci. 2014 Jun 11;34(24):8210-8. doi: 10.1523/JNEUROSCI.5456-13.2014. Erratum in: J Neurosci. 2015 Nov 25;35(47):15767.

13.

Sex differences in dopamine- and vesicular monoamine-transporter functions.

Dluzen DE, McDermott JL.

Ann N Y Acad Sci. 2008 Oct;1139:140-50. doi: 10.1196/annals.1432.010.

PMID:
18991858
14.

Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.

Nickell JR, Krishnamurthy S, Norrholm S, Deaciuc G, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP.

J Pharmacol Exp Ther. 2010 Feb;332(2):612-21. doi: 10.1124/jpet.109.160275.

15.

Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function.

Hofford RS, Darna M, Wilmouth CE, Dwoskin LP, Bardo MT.

Behav Brain Res. 2014 Aug 15;270:151-8. doi: 10.1016/j.bbr.2014.05.007.

16.

Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.

Hadlock GC, Chu PW, Walters ET, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2010 Oct;335(1):207-12. doi: 10.1124/jpet.110.166660.

17.

Phosphorylation of a vesicular monoamine transporter by casein kinase II.

Krantz DE, Peter D, Liu Y, Edwards RH.

J Biol Chem. 1997 Mar 7;272(10):6752-9.

19.

Monoamine transporter as a target molecule for psychostimulants.

Sora I, Li B, Fumushima S, Fukui A, Arime Y, Kasahara Y, Tomita H, Ikeda K.

Int Rev Neurobiol. 2009;85:29-33. doi: 10.1016/S0074-7742(09)85003-4. Review.

PMID:
19607959
20.

The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.

Pifl C, Reither H, Hornykiewicz O.

Eur J Pharmacol. 2015 May 15;755:119-26. doi: 10.1016/j.ejphar.2015.03.004.

PMID:
25771452
Items per page

Supplemental Content

Support Center